Human-Based Technologies in Cardiovascular Pharmacology Research.

Area of Science:

• Cardiovascular Pharmacology
• Biomedical Engineering
• Translational Medicine

Background:

• Traditional animal models have limitations in accurately reflecting human cardiovascular biology and disease.
• Existing drug development pipelines require more predictive and human-relevant testing platforms.

Purpose of the Study:

• To review the impact of human-based technologies on cardiovascular pharmacology.
• To highlight advancements in drug testing, mechanistic understanding, and translational relevance.
• To discuss the integration of complementary technologies and future challenges.

Main Methods:

• Utilized human-based platforms: tissue chips, microphysiological systems, engineered heart tissues, cardiac organoids, and human cardiac slices.
• Integrated biobanking, omics technologies, advanced imaging, digital health tools, and wearables.
• Applied artificial intelligence (AI), machine learning (ML), CRISPR/Cas9 genome editing, and in vitro to in vivo extrapolation (IVIVE) frameworks.

Main Results:

• Human-based approaches provide more accurate reflections of human biology and disease mechanisms.
• Significant improvements in drug testing accuracy, mechanistic insights, and translational relevance were observed.
• Multidimensional characterization of cardiovascular phenotypes is enabled by integrated technologies.

Conclusions:

• Human-based technologies are revolutionizing cardiovascular research, drug development, and personalized medicine.
• Addressing challenges in standardization, scalability, and ethical governance is crucial for full realization.
• Strategic investment and collaboration will drive the next generation of human-centric cardiovascular therapies.